Search

Your search keyword '"Taliani G."' showing total 50 results

Search Constraints

Start Over You searched for: Author "Taliani G." Remove constraint Author: "Taliani G." Topic medicine Remove constraint Topic: medicine
50 results on '"Taliani G."'

Search Results

1. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

2. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

3. Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia

4. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

5. Clinical, epidemiological and virological features of acute hepatitis B in Italy

6. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

7. Predictors of access and response to DAA in a cohort of human immunodeficincy virus/hepatitis C virus co-infected patients in Italy

8. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

9. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

10. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study

11. Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life

12. Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study

13. The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19

14. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

15. HepaDisk – A new quality of life questionnaire for HCV patients

16. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

17. Real life experiences in HCV management in 2018

18. Current and future challenges in HCV: insights from an Italian experts panel

19. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis

20. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

21. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

22. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

23. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

24. From current status to optimization of HCV treatment: Recommendations from an expert panel

25. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection

26. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study

27. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis

28. HCV cirrhotic patients treated with direct-acting antivirals: Detection of tubular dysfunction and resolution after viral clearance

29. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

30. Vitamin D deficiency and health-related quality of life in chronic hepatitis C

31. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

32. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

33. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

34. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients

35. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

36. Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT)

37. Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

38. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

39. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

40. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

41. GENDER DIFFERENCES IN HCV CHRONIC LIVER DISEASE: A REAL LIFE EVALUATION IN PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) COHORT STUDY

42. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients

43. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients

44. Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy

45. Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)

46. Surgical procedures as a major risk factor for chronic hepatitis C virus infection in Italy: Evidence from a case-control study

47. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study

48. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C

49. Levels of Pre-S antigens and HBV DNA in sera from high and low viremic HBV carriers

50. Hepatitis A: post-exposure prophylaxis

Catalog

Books, media, physical & digital resources